|
|
ZLB Behring Foundation Awards Grants to Benefit Bleeding Disorders Community
The ZLB Behring Foundation for Research and Advancement of Patient Health has recently awarded funding for programs designed to benefit the bleeding disorders community.
King of Prussia, PA — 05 June 2006
The ZLB Behring Foundation for Research and Advancement of Patient
Health has recently awarded funding for programs designed to benefit
the bleeding disorders community. The Foundation awards grants at regular
intervals throughout the year. In this cycle, nine recipients received
awards. The grants support a range of initiatives, such as those that
support and educate specific patient populations to research on the
genetic aspect of hemophilia.
Governed by an independent Advisory
Council with the sole authority to award grants, the ZLB Behring
Foundation is a non-profit organization dedicated exclusively to
charitable, scientific and educational purposes that advance the standard
of care for persons affected by bleeding disorders such as hemophilia and
von Willebrand Disease. Since its inception in 2001, the ZLB Behring
Foundation has awarded millions of dollars in grants to the bleeding
disorders community.
"We are confident that with our continued
support, researchers and advocates will continue to advance the quality
and standard of care for patients suffering from these rare and often
debilitating disorders," said Paul Perreault, Vice Director of the
ZLB Behring Foundation. "We strongly encourage all
eligible organizations and individuals to submit grant requests for
consideration."
Several of the Foundation grants awarded in this
round will fund research on and educational programs for women with
bleeding disorders. The National Hemophilia Foundation estimates that more
than two and a half million women in the United States have an undiagnosed
bleeding disorder. Women with undiagnosed bleeding disorders can often
experience life-threatening complications during childbirth, surgery,
accidents or injury, and are at higher risk for internal bleeding.
A grant to the Hemophilia Federation of America (HFA) will
help support its "Focus on the Feminine" program, an effort to educate
women across the United States on the signs and symptoms of bleeding
disorders. The funding will enable HFA to participate in health fairs
throughout the country.
In another program funded by the ZLB
Behring Foundation, Dr. Barbara Konkle of the University of
Pennsylvania will research the pattern of von Willebrand factor (vWF)
antigen fluctuation during pregnancy and post-partum in patients with von
Willebrand Disease (vWD). This information promises to have a significant
impact on the management of labor and delivery in women with vWD.
An additional grant will fund community-based, local outreach
initiatives such as "Building Healthy Father-Son Relationships," a weekend
retreat intended to strengthen the bond between fathers and sons in the
bleeding disorders community. The initiative, created by Inalex
Communications, will teach fathers and sons how to develop a
supportive, emotionally connected and trusting relationship with one
another.
Other ZLB Behring Foundation grant recipients
include:
- Carol Kasper, MD (Pasadena, CA): Monograph on Inheritance and
Other Genetic Aspects of Hemophilia.
- UMDNJ Robert Wood Johnson Medical School (Piscataway, NJ):
Protein Z Deficiency in Women with Placental Abruption
- Hemophilia of Iowa (Iowa City, Iowa): Kari Atkinson: First
Steps
- Hemophilia Federation of Nevada (Henderson, NV): Nevada
Native American Hemophilia Education/Family Support
- Utah Hemophilia Foundation (Salt Lake City, UT): Group Work
Works!
- Commonwealth Health Center Volunteer Association (Saipan):
Supporting Underserved Populations of Saipan and Tinian
About
the ZLB Behring Foundation
Founded in 2001 as an
independent, non-profit corporation, the ZLB Behring Foundation for
Research and Advancement of Patient Health is the only corporate
foundation dedicated exclusively to charitable, scientific and educational
purposes designed to advance the standard of care for persons affected by
bleeding disorders. The ZLB Behring Foundation is
governed by an Advisory Council consisting of healthcare professionals and
advocates who are renowned for their dedication to the bleeding disorders
community. The Advisory Council has the sole authority to award all
grants.
For more information on the Foundation, visit www.ZLBBehringFoundation.com.
About von
Willebrand Disease
Von Willebrand disease (VWD) is caused by a
deficiency or abnormality of the von Willebrand factor, a protein in the
blood that is necessary for normal blood clotting. Men and women are
equally likely to be affected by VWD. VWD is classified by types, ranging
from Type 1 (the most common and mild) to Type 3 (the most severe). VWD
affects about 60 million people worldwide.
Women with VWD are more
likely to experience heavy, prolonged menstruation. Other common symptoms
of VWD include frequent nosebleeds and easy bruising. Bleeding can be mild
or serious and can occur as a result of injury, or without any obvious
cause. More serious symptoms include bleeding into joints and internal
organs. The VWD patient may require special care during dental procedures,
surgery and childbirth.
There is no cure for VWD, but it can be
treated.
About ZLB Behring
ZLB Behring is a global
leader in the plasma protein biotherapeutics industry. Its comprehensive
line of therapies include products for the treatment of hemophilia and
other coagulation disorders, immunoglobulins for the prevention and
treatment of immune disorders, treatments that inhibit the formation of
blood clots, wound-healing agents used during major surgical procedures,
and plasma expanders for the treatment of a variety of conditions such as
shock, burns and circulatory disorders. Additionally, ZLB Behring operates
one of the world's largest, fully-owned plasma collection networks. ZLB
Behring is a subsidiary of CSL Limited, a bio-pharmaceutical company which
operates worldwide from its headquarters in Melbourne, Australia. |
Contact: |
|
| Name: |
Sheila A. Burke |
| Title: |
Director, Communications & Public
Relations
ZLB Behring |
| Department: |
Worldwide Commercial Operations |
| Phone: |
610-878-4209
484-919-2618 (Mobile) |
| Fax: |
610-878-4219 |
| E-mail: |
Sheila.Burke@zlbbehring.com |
| |
|
| Name: |
Roger Bentley |
| Title: |
Senior Director, Corporate
Communications |
| Department: |
Media Inquires US |
| Phone: |
+1-610-878-4155 |
| E-mail: |
roger.bentley@zlbbehring.com |
| |
| |
|